Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management

MT Newswires Live07-27

Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged trade secret misappropriation by Avilar Therapeutics and RA Capital Management.

The jury found that after Yale shared confidential technical information about its MODA targeted protein degradation platform with RA Capital related to a possible deal, RA Capital shared the technology with Avilar Therapeutics to develop a rival platform, the company said.

Biohaven said it licensed the MODA platform from Yale, which was developed by Yale professor David Spiegel, to develop and commercialize the technology.

Yale received $2 million for RA Capital's breach of contract, and $1 million for trade secret misappropriation.

"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously," Biohaven Chief Executive Vlad Coric said in a statement.

Avilar and RA Capital did not immediately respond to a request to comment from MT Newswires.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654172210?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654172210","market":"us","top_or_hot":-1,"title":"Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management","media":"MT Newswires Live","content":"<html><body><p> Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged trade secret misappropriation by Avilar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and RA Capital Management.</p><p>The jury found that after Yale shared confidential technical information about its MODA targeted protein degradation platform with RA Capital related to a possible deal, RA Capital shared the technology with Avilar Therapeutics to develop a rival platform, the company said.</p><p>Biohaven said it licensed the MODA platform from Yale, which was developed by Yale professor David Spiegel, to develop and commercialize the technology.</p><p>Yale received $2 million for RA Capital's breach of contract, and $1 million for trade secret misappropriation.</p><p>\"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously,\" Biohaven Chief Executive Vlad Coric said in a statement.</p><p>Avilar and RA Capital did not immediately respond to a request to comment from MT Newswires.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven Awarded $1 Million Over Alleged Trade Secret Violations by Avilar Therapeutics, RA Capital Management\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-27 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged trade secret misappropriation by Avilar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and RA Capital Management.</p><p>The jury found that after Yale shared confidential technical information about its MODA targeted protein degradation platform with RA Capital related to a possible deal, RA Capital shared the technology with Avilar Therapeutics to develop a rival platform, the company said.</p><p>Biohaven said it licensed the MODA platform from Yale, which was developed by Yale professor David Spiegel, to develop and commercialize the technology.</p><p>Yale received $2 million for RA Capital's breach of contract, and $1 million for trade secret misappropriation.</p><p>\"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously,\" Biohaven Chief Executive Vlad Coric said in a statement.</p><p>Avilar and RA Capital did not immediately respond to a request to comment from MT Newswires.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654172210","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654172210","pubTimestamp":1785154225,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biohaven  said Monday that a federal jury has awarded it $1 million in damages over an alleged trade secret misappropriation by Avilar Therapeutics and RA Capital Management.The jury found that after Yale shared confidential technical information about its MODA targeted protein degradation platform with RA Capital related to a possible deal, RA Capital shared the technology with Avilar Therapeutics to develop a rival platform, the company said.Biohaven said it licensed the MODA platform from Yale, which was developed by Yale professor David Spiegel, to develop and commercialize the technology.Yale received $2 million for RA Capital's breach of contract, and $1 million for trade secret misappropriation.\"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously,\" Biohaven Chief Executive Vlad Coric said in a statement.Avilar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RA":"Brookfield Real Assets Income Fund Inc.","LENZ":"Therapeutics","BK4539":"次新股","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","BK4139":"生物科技","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"Biohaven 因 Avilar Therapeutics 和 RA Capital Management 涉嫌侵犯商业秘密而获得 100 万美元赔偿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RA":1.5,"BHVN":1,"LENZ":1.5},"content_text":"Biohaven (BHVN) said Monday that a federal jury has awarded it $1 million in damages over an alleged trade secret misappropriation by Avilar Therapeutics and RA Capital Management.The jury found that after Yale shared confidential technical information about its MODA targeted protein degradation platform with RA Capital related to a possible deal, RA Capital shared the technology with Avilar Therapeutics to develop a rival platform, the company said.Biohaven said it licensed the MODA platform from Yale, which was developed by Yale professor David Spiegel, to develop and commercialize the technology.Yale received $2 million for RA Capital's breach of contract, and $1 million for trade secret misappropriation.\"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously,\" Biohaven Chief Executive Vlad Coric said in a statement.Avilar and RA Capital did not immediately respond to a request to comment from MT Newswires.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654172210","isCrawlerRequest":true}